Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mwangi J. Murage, Adrienne M. Gilligan, Oth Tran, Orin Goldblum, Russel Burge, Chen-Yen Lin & Abrar Qureshi. (2021) Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. Journal of Dermatological Treatment 32:1, pages 56-63.
Read now
Read now
Ritam Chowdhury, Jessica Franchino-Elder, Li Wang, Huseyin Yuce, Cheng Wang & Briain O. Hartaigh. (2019) Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. Journal of Medical Economics 22:12, pages 1338-1350.
Read now
Read now
Adrienne M. Gilligan, Jessica Franchino-Elder, Xue Song, Cheng Wang, Caroline Henriques, Amy Sainski-Nguyen, Kathleen Wilson, David M. Smith & Stephen Sander. (2019) Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 203-212.
Read now
Read now
Articles from other publishers (6)
Alessandra Buja, Vincenzo Rebba, Laura Montecchio, Giulia Renzo, Vincenzo Baldo, Silvia Cocchio, Nicola Ferri, Federico Migliore, Alessandro Zorzi, Brendan Collins, Cheïma Amrouch, Delphine De Smedt, Christodoulos Kypridemos, Mirko Petrovic, Martin O’Flaherty & Gregory Y.H. Lip. (2024) The Cost of Atrial Fibrillation: A Systematic Review. Value in Health 27:4, pages 527-541.
Crossref
Crossref
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse & Nicolas Danchin. (2022) Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. The European Journal of Health Economics 24:6, pages 867-875.
Crossref
Crossref
Javed Butler, Laurence M. Djatche, Baanie Sawhney, Sreya Chakladar, Lingfeng Yang, Joanne E. Brady & Mei Yang. (2020) Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. Advances in Therapy 37:9, pages 4015-4032.
Crossref
Crossref
Ashley Chen, Eric Stecker & Bruce A. Warden. (2020) Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. Journal of the American Heart Association 9:13.
Crossref
Crossref
Jessica Franchino‐Elder, Adrienne Gilligan, Xue Song, Briain O Hartaigh, Caroline Henriques, Amy Sainski‐Nguyen & Cheng Wang. (2020) Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant. Journal of Pharmaceutical Health Services Research 11:2, pages 133-140.
Crossref
Crossref
Panayiotis D. Ziakas, Irene S. Kourbeti, Loukia S. Poulou, Georgios S. Vlachogeorgos & Eleftherios Mylonakis. (2018) Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the “rubber effect”. PLOS ONE 13:6, pages e0198674.
Crossref
Crossref